<VariationArchive VariationID="2128789" VariationName="NM_000551.4(VHL):c.189_193dup (p.Ser65fs)" VariationType="Duplication" Accession="VCV002128789" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2178812" VariationID="2128789">
      <GeneList>
        <Gene Symbol="VHL" FullName="von Hippel-Lindau tumor suppressor" GeneID="7428" HGNC_ID="HGNC:12687" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10141778" stop="10153667" display_start="10141778" display_stop="10153667" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183318" stop="10195353" display_start="10183318" display_stop="10195353" Strand="+" />
          </Location>
          <OMIM>608537</OMIM>
          <Haploinsufficiency last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000551.4(VHL):c.189_193dup (p.Ser65fs)</Name>
      <CanonicalSPDI>NC_000003.12:10142032:GCTGCGCT:GCTGCGCTGCGCT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10142032" stop="10142033" display_start="10142032" display_stop="10142033" variantLength="5" positionVCF="10142032" referenceAlleleVCF="T" alternateAlleleVCF="TGCTGC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183716" stop="10183717" display_start="10183716" display_stop="10183717" variantLength="5" positionVCF="10183716" referenceAlleleVCF="T" alternateAlleleVCF="TGCTGC" />
      </Location>
      <ProteinChange>S65fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_322" sequenceAccession="LRG_322">
            <Expression>LRG_322:g.5402_5406dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_322t1" sequenceAccession="LRG_322t1">
            <Expression>LRG_322t1:c.189_193dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_322p1" sequenceAccession="LRG_322p1" change="p.Ser65Cysfs">
            <Expression>LRG_322p1:p.Ser65Cysfs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10183720_10183724dup" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10183720_10183724dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.10142036_10142040dup" Assembly="GRCh38">
            <Expression>NC_000003.12:g.10142036_10142040dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008212.3" sequenceAccession="NG_008212" sequenceVersion="3" change="g.5402_5406dup">
            <Expression>NG_008212.3:g.5402_5406dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000551.4" sequenceAccession="NM_000551" sequenceVersion="4" change="c.189_193dup" MANESelect="true">
            <Expression>NM_000551.4:c.189_193dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000542.1" sequenceAccession="NP_000542" sequenceVersion="1" change="p.Ser65fs">
            <Expression>NP_000542.1:p.Ser65fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354723.2" sequenceAccession="NM_001354723" sequenceVersion="2" change="c.189_193dup">
            <Expression>NM_001354723.2:c.189_193dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001341652.1" sequenceAccession="NP_001341652" sequenceVersion="1" change="p.Ser65fs">
            <Expression>NP_001341652.1:p.Ser65fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_198156.3" sequenceAccession="NM_198156" sequenceVersion="3" change="c.189_193dup">
            <Expression>NM_198156.3:c.189_193dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_937799.1" sequenceAccession="NP_937799" sequenceVersion="1" change="p.Ser65fs">
            <Expression>NP_937799.1:p.Ser65fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_176335.1" sequenceAccession="NR_176335" sequenceVersion="1" change="n.259_263dup">
            <Expression>NR_176335.1:n.259_263dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000551.4(VHL):c.189_193dup (p.Ser65fs) AND multiple conditions" Accession="RCV003057752" Version="2">
        <ClassifiedConditionList TraitSetID="23764">
          <ClassifiedCondition DB="MedGen" ID="C1837915">Chuvash polycythemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0019562">Von Hippel-Lindau syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-09" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12202531</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29891534</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31350093</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8956040</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="23764" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6116" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Von Hippel-Lindau</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Von Hippel-Lindau syndrome</ElementValue>
                <XRef ID="Von+Hippel-Lindau+syndrome/7416" DB="Genetic Alliance" />
                <XRef ID="46659004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VHL syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VHLS</ElementValue>
                <XRef Type="MIM" ID="193300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.</Attribute>
                <XRef ID="NBK1463" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000552165" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000314230" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569658" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7855" />
                <XRef ID="7855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301636</ID>
                <ID Source="BookShelf">NBK1463</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Von Hippel-Lindau">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome</URL>
                <CitationText>PDQÂ® Cancer Genetics Editorial Board. PDQ Von Hippel-Lindau Disease. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="892" DB="Orphanet" />
              <XRef ID="C0019562" DB="MedGen" />
              <XRef ID="MONDO:0008667" DB="MONDO" />
              <XRef Type="MIM" ID="193300" DB="OMIM" />
            </Trait>
            <Trait ID="1779" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Erythrocytosis, familial, 2</ElementValue>
                <XRef ID="Erythrocytosis%2C+familial%2C+2/8355" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Chuvash polycythemia</ElementValue>
                <XRef ID="MONDO:0009892" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, VHL-DEPENDENT</ElementValue>
                <XRef Type="MIM" ID="263400" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CP</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ECYT2</ElementValue>
                <XRef Type="MIM" ID="263400" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17176" />
                <XRef ID="17176" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2012">
                <ID Source="PubMed">22274579</ID>
              </Citation>
              <XRef ID="238557" DB="Orphanet" />
              <XRef ID="C1837915" DB="MedGen" />
              <XRef ID="MONDO:0009892" DB="MONDO" />
              <XRef Type="MIM" ID="263400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6042849" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="16462102|MedGen:C0019562;C1837915" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003350169" DateUpdated="2024-02-28" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8956040</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12202531</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29891534</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31350093</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with VHL-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser65Cysfs*4) in the VHL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VHL are known to be pathogenic (PMID: 8956040, 12202531, 29891534, 31350093).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VHL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.10183716_10183717insGCTGC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0019562" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1837915" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6042849" TraitType="Disease" MappingType="XRef" MappingValue="C0019562" MappingRef="MedGen">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6042849" TraitType="Disease" MappingType="XRef" MappingValue="C1837915" MappingRef="MedGen">
        <MedGen CUI="C1837915" Name="Chuvash polycythemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

